person · Reporting owner
WEATHERMAN ELIZABETH H
Disclosed activity across 6 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INSULET CORPPODD · Entity 3516 | Director | June 03, 2026 | June 03, 2026 |
| Royalty Pharma plcRPRX · Entity 3100 | Director | June 05, 2026 | June 08, 2026 |
| VAPOTHERM INCVAPO · Entity 87270 | Director | September 20, 2024 | September 24, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INSULET CORP
Report date June 03, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,352 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Purchase · Acquired 3,450 · Balance 10,352 F1: The price reported represents the weighted average purchase price of the shares acquired. The shares were purchased in multiple transactions at prices ranging from $143.21 to $145. Specifically: 1,607 shares were purchased in the range of $143.21 to $144.13, at a weighted average share price of $143.65; 1,843 shares were purchased in the range of $144.22 to $145, at a weighted average share price of $144.69. F2: Footnote continued: The Reporting Person hereby undertakes, upon the request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported represents the weighted average purchase price of the shares acquired. The shares were purchased in multiple transactions at prices ranging from $143.21 to $145. Specifically: 1,607 shares were purchased in the range of $143.21 to $144.13, at a weighted average share price of $143.65; 1,843 shares were purchased in the range of $144.22 to $145, at a weighted average share price of $144.69.
F2: Footnote continued: The Reporting Person hereby undertakes, upon the request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.
Royalty Pharma plc
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary SharesSEC Table I · non-derivative | Direct | 13,103 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 4,545 · Balance 13,103 F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.
VAPOTHERM INC
Report date September 20, 2024 · Filed September 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-09-20 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2024-09-20 · Disposition to issuer · Disposed 14,555 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger, dated as of June 17, 2024, among Veronica Holdings, LLC, Veronica Intermediate Holdings, LLC, Veronica Merger Sub, Inc. and Vapotherm, Inc. (Company), in exchange for a cash payment of $2.18 per share. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-09-20 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2024-09-20 · Disposition to issuer · Disposed 3,000 · Balance 0 F2: The restricted stock unit awards, which these shares were subject to, were canceled in the merger in exchange for a cash payment of $2.18 per underlying share. |
| Common StockSEC Table I · non-derivative | IndirectElizabeth H. Weatherman Revocable Trust | 0 |
Reported balance
After 2024-09-20 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2024-09-20 · Disposition to issuer · Disposed 81,546 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger, dated as of June 17, 2024, among Veronica Holdings, LLC, Veronica Intermediate Holdings, LLC, Veronica Merger Sub, Inc. and Vapotherm, Inc. (Company), in exchange for a cash payment of $2.18 per share. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $150.00 · Expires 2029-07-24 | Direct | 0 |
Reported balance
After 2024-09-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-09-20 · Disposition to issuer · Disposed 1,187 · Balance 0 F3: This option, which provided for vesting in full on the earlier of the first anniversary of the date of grant or the date of the Company's 2020 annual meeting of stockholders, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Company common stock underlying the option, multiplied by (b) the excess, if any, of $2.18 over the per share exercise price of such option, which cash payment was $0.00 since this option had an exercise price that exceeded $2.18. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.48 · Expires 2032-07-27 | Direct | 0 |
Reported balance
After 2024-09-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-09-20 · Disposition to issuer · Disposed 1,089 · Balance 0 F4: This option, which provided for vesting in full on the earlier of the first anniversary of the date of grant or the date of the Company's 2023 annual meeting of stockholders, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Company common stock underlying the option, multiplied by (b) the excess, if any, of $2.18 over the per share exercise price of such option, which cash payment was $0.00 since this option had an exercise price that exceeded $2.18. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger, dated as of June 17, 2024, among Veronica Holdings, LLC, Veronica Intermediate Holdings, LLC, Veronica Merger Sub, Inc. and Vapotherm, Inc. (Company), in exchange for a cash payment of $2.18 per share.
F2: The restricted stock unit awards, which these shares were subject to, were canceled in the merger in exchange for a cash payment of $2.18 per underlying share.
F3: This option, which provided for vesting in full on the earlier of the first anniversary of the date of grant or the date of the Company's 2020 annual meeting of stockholders, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Company common stock underlying the option, multiplied by (b) the excess, if any, of $2.18 over the per share exercise price of such option, which cash payment was $0.00 since this option had an exercise price that exceeded $2.18.
F4: This option, which provided for vesting in full on the earlier of the first anniversary of the date of grant or the date of the Company's 2023 annual meeting of stockholders, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Company common stock underlying the option, multiplied by (b) the excess, if any, of $2.18 over the per share exercise price of such option, which cash payment was $0.00 since this option had an exercise price that exceeded $2.18.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NEVRO CORP
Report date April 03, 2025 · Filed April 03, 2025
Section 16 reporting ended · disclosed 2025-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-04-03 transaction · row 1
1 source rowRow 1 · 2025-04-03 · Disposition to issuer · Disposed 86,171 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time"). F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time").
F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration.
Silk Road Medical Inc
Report date September 17, 2024 · Filed September 19, 2024
Section 16 reporting ended · disclosed 2024-09-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-09-17 transaction · row 1
1 source rowRow 1 · 2024-09-17 · Disposition to issuer · Disposed 155,004 · Balance 0 F1: Of the reported shares, 5,859 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock. F2: Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes. F3: Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2026-08-04 | Direct | 0 |
Reported balance
After 2024-09-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-09-17 · Disposition to issuer · Disposed 35,185 · Balance 0 F4: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $911,291.50, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2029-04-03 | Direct | 0 |
Reported balance
After 2024-09-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-09-17 · Disposition to issuer · Disposed 8,910 · Balance 0 F5: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $66,825.00, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions. |
Filing footnotes · ownership attribution and instrument terms
F1: Of the reported shares, 5,859 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock.
F2: Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes.
F3: Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions.
F4: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $911,291.50, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.
F5: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $66,825.00, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.
Wright Medical Group N.V.
Report date November 11, 2020 · Filed November 13, 2020
Section 16 reporting ended · disclosed 2020-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 1
1 source rowRow 1 · 2020-11-11 · Other · Disposed 38,084 · Balance 0 F1: On November 4, 2019, Wright Medical Group N.V. (the Issuer) entered into a purchase agreement (the Purchase Agreement) with Stryker Corporation and its subsidiary, Stryker B.V. (the Purchaser). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR 0.03 per share (Shares), of the Issuer (the Offer), and on November 11, 2020 (the Acceptance Time), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer, including 38,084 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the Offer Consideration), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.84 · Expires 2029-07-26 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-11-11 · Disposition to issuer · Disposed 11,691 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.49 · Expires 2028-07-24 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-11 · Disposition to issuer · Disposed 9,907 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.86 · Expires 2027-07-25 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-11 · Disposition to issuer · Disposed 10,275 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.24 · Expires 2026-07-19 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-11-11 · Disposition to issuer · Disposed 11,765 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 4, 2019, Wright Medical Group N.V. (the Issuer) entered into a purchase agreement (the Purchase Agreement) with Stryker Corporation and its subsidiary, Stryker B.V. (the Purchaser). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR 0.03 per share (Shares), of the Issuer (the Offer), and on November 11, 2020 (the Acceptance Time), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer, including 38,084 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the Offer Consideration), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement).
F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2022 Filed Jul 5, 2022 20:34 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 452 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-013694 · doc1.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,452 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 4,155 restricted stock units. Read SEC document |
| June 09, 2022 Filed Jun 15, 2022 10:01 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantOption (right to buy) · Derivative | 2,771 | $0.00 Strike: $36.90 | $0.00 |
DisclosureSEC source: 0001593968-22-001138 · primary_01.xml · derivative · entry 3 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,771 Underlying: Common Stock · 2,771 shares Expires 2032-06-09 F3 · shares: The shares subject to the options represent cash retainer that the Reporting Person elected to receive in the form of stock options. F4 · derivative.exercise_date: One fourth of the shares subject to the option shall vest on each of September 5, 2022, December 5, 2022, March 5, 2023, and the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 09, 2022 Filed Jun 15, 2022 10:01 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantOption (right to buy) · Derivative | 5,195 | $0.00 Strike: $36.90 | $0.00 |
DisclosureSEC source: 0001593968-22-001138 · primary_01.xml · derivative · entry 2 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,195 Underlying: Common Stock · 5,195 shares Expires 2032-06-09 F2 · derivative.exercise_date: All of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date the award is granted or (ii) the day prior to the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 09, 2022 Filed Jun 15, 2022 10:01 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantCommon Stock | 846 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-001138 · primary_01.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,454 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of SILK common stock. All of the RSUs vest on the earlier of (i) the one-year anniversary of the date the award is granted or (ii) the day prior to the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 26, 2022 Filed May 27, 2022 20:58 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 4,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-011885 · doc1.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 26, 2022 or (ii) the next Annual Meeting following May 26, 2022, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 4,155 restricted stock units. Read SEC document |
| May 24, 2022 Filed May 26, 2022 20:14 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 1,009 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-015768 · form4.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,241 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs vest in full on April 30, 2023 and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:47 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 273 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-008042 · doc1.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,845 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 1,167 restricted stock units. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:46 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 273 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-008041 · doc1.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,845 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 1,167 restricted stock units. Read SEC document |
| February 04, 2022 Filed Feb 7, 2022 21:15 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 1,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003515 · form4.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,232 F1 · shares: Initial equity award in the form of restricted stock units ("RSUs"). RSUs vest 50% on the first anniversary of the date of grant and 25% on each of the second and third anniversaries of the date of grant. The RSUs are settled in shares of common stock on a one-for-one basis. Read SEC document |
| January 01, 2022 Filed Jan 5, 2022 02:43 UTC | VAPOTHERM INC VAPO · Entity 87270 | GrantCommon Stock | 2,897 | $20.71 | $59,996.87 |
DisclosureSEC source: 0001235802-22-000011 · primary_doc.xml · nonDerivative · entry 2 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,441 F3 · shares: Restricted stock unit award in lieu of cash retainers in the aggregate amount of $60,000 for fiscal year 2022 under the Vapotherm, Inc. 2018 Equity Incentive Plan pursuant to the terms of the Vapotherm, Inc. Non-Employee Director Compensation Policy. The restricted stock unit award will vest in four nearly equal installments on each of March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022. F4 · balance_after: Includes 8,289 shares that will be issued over time subject to restricted stock units granted under the Vapotherm, Inc. 2018 Equity Incentive Plan. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 18:04 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 244 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000348 · doc1.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,572 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 3,183 restricted stock units. Read SEC document |
| December 31, 2021 Filed Jan 5, 2022 02:43 UTC | VAPOTHERM INC VAPO · Entity 87270 | GrantCommon Stock | 2,897 | $20.71 | $59,996.87 |
DisclosureSEC source: 0001235802-22-000011 · primary_doc.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,544 F1 · shares: Stock award in lieu of cash retainers for fiscal year 2021 under the Vapotherm, Inc. 2018 Equity Incentive Plan pursuant to the terms of the Vapotherm, Inc. Non-Employee Director Compensation Policy. F2 · balance_after: Includes 5,392 shares that will be issued over time subject to restricted stock units granted under the Vapotherm, Inc. 2018 Equity Incentive Plan. Read SEC document |
| November 22, 2021 Filed Nov 22, 2021 18:49 UTC | NEVRO CORP NVRO · Entity 12422 | PurchaseCommon Stock | 10,703 | $85.74 | $917,649.53 |
DisclosureSEC source: 0001567619-21-020998 · doc1.xml · nonDerivative · entry 2 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,328 F3 · price: The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $85.30 to $86.15, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 3,183 restricted stock units. Read SEC document |
| November 22, 2021 Filed Nov 22, 2021 18:49 UTC | NEVRO CORP NVRO · Entity 12422 | PurchaseCommon Stock | 9,297 | $84.86 | $788,898.79 |
DisclosureSEC source: 0001567619-21-020998 · doc1.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,625 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $84.29 to $85.27, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 3,183 restricted stock units. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 18:33 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 170 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-017864 · doc1.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,328 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 3,183 restricted stock units. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 20:53 UTC | VAPOTHERM INC VAPO · Entity 87270 | GrantCommon Stock | 5,392 | $0.00 | $0.00 |
DisclosureSEC source: 0001235802-21-000089 · primary_doc.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,647 F1 · shares: This annual award in the form of restricted stock units was granted under the Vapotherm, Inc. 2018 Equity Incentive Plan pursuant to the terms of the Vapotherm, Inc. Amended and Restated Non-Employee Director Compensation Policy. The restricted stock units are eligible to vest in full on the earlier of the first anniversary of the date of grant or the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service as a director of the Issuer through the vesting date. F2 · balance_after: Includes 5,392 shares that will be issued over time subject to restricted stock units granted under the Vapotherm, Inc. 2018 Equity Incentive Plan. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 17:27 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 119 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-012951 · doc1.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,158 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 3,183 restricted stock units. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 22:37 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantOption (right to buy) · Derivative | 2,357 | $0.00 Strike: $50.40 | $0.00 |
DisclosureSEC source: 0001593968-21-001669 · primary_01.xml · derivative · entry 3 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,357 Underlying: Common Stock · 2,357 shares Expires 2031-06-17 F3 · shares: The shares subject to the options represent cash retainer that the Reporting Person elected to receive in the form of stock options. F4 · derivative.exercise_date: One fourth of the shares subject to the option shall vest on each of September 5, 2021, December 5, 2021, March 5, 2022, and the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 22:37 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantOption (right to buy) · Derivative | 4,066 | $0.00 Strike: $50.40 | $0.00 |
DisclosureSEC source: 0001593968-21-001669 · primary_01.xml · derivative · entry 2 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,066 Underlying: Common Stock · 4,066 shares Expires 2031-06-17 F2 · derivative.exercise_date: All of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date the award is granted or (ii) the day prior to the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 22:37 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantCommon Stock | 570 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-001669 · primary_01.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,608 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of SILK common stock. All of the RSUs vest on the earlier of (i) the one-year anniversary of the date the award is granted or (ii) the day prior to the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 28, 2021 Filed Jun 3, 2021 01:23 UTC | Silk Road Medical Inc SILK · Entity 87417 | Disposition to issuerCommon Stock | 33,000 | $50.00 | $1,650,000.00 |
DisclosureSEC source: 0001593968-21-001512 · primary_01.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,038 F1 · kind: The sale reported on this Form 4 was effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on March 11, 2021. Read SEC document |
| May 28, 2021 Filed Jun 4, 2021 00:29 UTC Amendment | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 33,000 | $50.00 | $1,650,000.00 |
DisclosureSEC source: 0001593968-21-001529 · primary_01.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,038 F1 · kind: The original Form 4, filed on June 2, 2021, is being amended by this Form 4 solely to correct an administrative error, which misreported the sale as Transaction Code "D." F2 · kind: The sale reported on this Form 4 was effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on March 11, 2021. Read SEC document |
| May 25, 2021 Filed May 26, 2021 20:59 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 1,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-011220 · doc1.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,039 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 25, 2021 or (ii) the next Annual Meeting following May 25, 2021, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 3,183 RSUs. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 16:53 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 147 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-007522 · doc1.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,872 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 5,408 restricted stock units. Read SEC document |
| January 20, 2021 Filed Jan 21, 2021 21:12 UTC | VAPOTHERM INC VAPO · Entity 87270 | GrantCommon Stock | 469 | $31.98 | $14,998.62 |
DisclosureSEC source: 0001562180-21-000434 · primarydocument.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,255 F1 · shares: Compensation for services rendered during fourth quarter of 2020 in accordance with the company's non-employee director compensation plan and the company's equity plan. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 17:25 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 99 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-000323 · doc1.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,725 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 5,408 restricted stock units. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 16:43 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerStock Option (right to buy) · Derivative | 11,765 | Not disclosed Strike: $21.24 | Not disclosed |
DisclosureSEC source: 0001235802-20-000130 · primary_doc.xml · derivative · entry 5 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 11,765 shares Expires 2026-07-19 F2 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 16:43 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerStock Option (right to buy) · Derivative | 10,275 | Not disclosed Strike: $27.86 | Not disclosed |
DisclosureSEC source: 0001235802-20-000130 · primary_doc.xml · derivative · entry 4 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 10,275 shares Expires 2027-07-25 F2 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 16:43 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerStock Option (right to buy) · Derivative | 9,907 | Not disclosed Strike: $24.49 | Not disclosed |
DisclosureSEC source: 0001235802-20-000130 · primary_doc.xml · derivative · entry 3 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,907 shares Expires 2028-07-24 F2 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 16:43 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerStock Option (right to buy) · Derivative | 11,691 | Not disclosed Strike: $27.84 | Not disclosed |
DisclosureSEC source: 0001235802-20-000130 · primary_doc.xml · derivative · entry 2 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 11,691 shares Expires 2029-07-26 F2 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 16:43 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | OtherOrdinary Shares, par value EUR 0.03 per share | 38,084 | $30.75 | $1,171,083.00 |
DisclosureSEC source: 0001235802-20-000130 · primary_doc.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On November 4, 2019, Wright Medical Group N.V. (the Issuer) entered into a purchase agreement (the Purchase Agreement) with Stryker Corporation and its subsidiary, Stryker B.V. (the Purchaser). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR 0.03 per share (Shares), of the Issuer (the Offer), and on November 11, 2020 (the Acceptance Time), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer, including 38,084 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the Offer Consideration), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement). Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 20:06 UTC | VAPOTHERM INC VAPO · Entity 87270 | GrantCommon Stock | 500 | $29.95 | $14,975.00 |
DisclosureSEC source: 0001562180-20-006374 · primarydocument.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,786 F1 · shares: Compensation for services rendered during third quarter of 2020 in accordance with the Issuer's non-employee director compensation plan and the Issuer's equity plan. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 16:53 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 123 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-017490 · doc1.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,626 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 5,408 restricted stock units. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:01 UTC | VAPOTHERM INC VAPO · Entity 87270 | GrantCommon Stock | 4,118 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-005831 · primarydocument.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,286 F1 · shares: Annual award in the form of restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's amended and restated Non-Employee Director Compensation Policy. This RSU is eligible to vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's 2021 annual meeting of stockholders. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:03 UTC | VAPOTHERM INC VAPO · Entity 87270 | GrantCommon Stock | 299 | $50.09 | $14,976.91 |
DisclosureSEC source: 0001562180-20-005160 · primarydocument.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,168 F1 · shares: Compensation for services rendered during second quarter of 2020 in accordance with the Issuer's non-employee director compensation plan and the Issuer's equity plan. Read SEC document |
| July 08, 2020 Filed Jul 11, 2020 01:09 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantOption (right to buy) · Derivative | 3,014 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001593968-20-001621 · primary_01.xml · derivative · entry 3 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,014 Underlying: Common Stock · 3,014 shares Expires 2030-07-08 F3 · shares: The shares subject to the options represent cash retainer and any additional fees that the Reporting Person elected to receive in the form of stock options. F4 · derivative.exercise_date: One fourth of the shares subject to the option shall vest on each of September 5, 2020, December 5, 2020, March 5, 2021, and the date of the Issuer's 2021 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| July 08, 2020 Filed Jul 11, 2020 01:09 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantOption (right to buy) · Derivative | 4,482 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001593968-20-001621 · primary_01.xml · derivative · entry 2 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,482 Underlying: Common Stock · 4,482 shares Expires 2030-07-08 F2 · derivative.exercise_date: All of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date the award is granted or (ii) the day prior to the date of the Issuer's 2021 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| July 08, 2020 Filed Jul 11, 2020 01:09 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantCommon Stock | 644 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-20-001621 · primary_01.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,038 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of SILK common stock. All of the RSUs vest on the earlier of (i) the one-year anniversary of the date the award is granted or (ii) the day prior to the date of the Issuer's 2021 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 18:50 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 72 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-012891 · doc1.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,503 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 5,408 restricted stock units. Read SEC document |
| May 21, 2020 Filed May 26, 2020 14:28 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 1,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-011143 · doc1.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,431 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 21, 2020 or (ii) the next Annual Meeting following May 21, 2020, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 5,408 restricted stock units. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 20:16 UTC | VAPOTHERM INC VAPO · Entity 87270 | GrantCommon Stock | 831 | $18.04 | $14,991.24 |
DisclosureSEC source: 0001562180-20-003041 · primarydocument.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,869 F1 · shares: Compensation for services rendered during first quarter of 2020 in accordance with the company's non-employee director compensation plan and the company's equity plan. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 16:41 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 172 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-007441 · doc1.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,055 F1 · shares: Fully vested restricted stock. The restricted stock represent quarterly retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash. F2 · balance_after: Includes 4,032 restricted stock units. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:29 UTC | VAPOTHERM INC VAPO · Entity 87270 | GrantCommon Stock | 1,290 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-000132 · primarydocument.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,038 F1 · shares: Compensation for services rendered during fourth quarter of 2019 in accordance with the company's non-employee director compensation plan and the company's equity plan. Read SEC document |
| January 02, 2020 Filed Mar 10, 2020 20:36 UTC Amendment | VAPOTHERM INC VAPO · Entity 87270 | GrantCommon Stock | 1,290 | $11.62 | $14,989.80 |
DisclosureSEC source: 0001562180-20-002357 · primarydocument.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,038 F1 · shares: Compensation for services rendered during fourth quarter of 2019 in accordance with the company's non-employee director compensation plan and the company's equity plan. Read SEC document |
| October 16, 2019 Filed Oct 17, 2019 20:07 UTC | VAPOTHERM INC VAPO · Entity 87270 | GrantCommon Stock | 1,491 | $10.06 | $14,999.46 |
DisclosureSEC source: 0001562180-19-005176 · primarydocument.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,748 F1 · shares: Compensation for services rendered during third quarter of 2019 in accordance with the company's non-employee director compensation plan and the company's equity plan. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 15:21 UTC | VAPOTHERM INC VAPO · Entity 87270 | PurchaseCommon Stock | 8,382 | $11.38 | $95,387.16 |
DisclosureSEC source: 0001562180-19-004693 · primarydocument.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Elizabeth H. Weatherman Revocable Trust Disclosed balance after: 76,530 F1 · price: This transaction was executed in multiple trades at prices ranging from $11.20 to $11.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 05, 2019 Filed Sep 6, 2019 20:20 UTC | VAPOTHERM INC VAPO · Entity 87270 | PurchaseCommon Stock | 2,457 | $10.93 | $26,855.01 |
DisclosureSEC source: 0001562180-19-004688 · primarydocument.xml · nonDerivative · entry 2 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Elizabeth H. Weatherman Revocable Trust Disclosed balance after: 68,148 F3 · price: This transaction was executed in multiple trades at prices ranging from $10.82 to $11.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 04, 2019 Filed Sep 6, 2019 20:20 UTC | VAPOTHERM INC VAPO · Entity 87270 | PurchaseCommon Stock | 3,531 | $10.29 | $36,333.99 |
DisclosureSEC source: 0001562180-19-004688 · primarydocument.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Elizabeth H. Weatherman Revocable Trust Disclosed balance after: 65,691 F1 · price: This transaction was executed in multiple trades at prices ranging from $10.22 to $10.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Amount of securities beneficially owned by the Elizabeth H. Weatherman Revocable Trust following reported transaction includes 24,844 shares that were previously reported as directly owned by the Reporting Person. Read SEC document |
| August 15, 2019 Filed Aug 15, 2019 16:17 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | PurchaseOrdinary Shares, par value EUR 0.03 per share | 15,000 | $20.87 | $313,050.00 |
DisclosureSEC source: 0001235802-19-000102 · primary_doc.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,084 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.78 to $20.93, inclusive. The reporting person undertakes to provide to Wright Medical Group N.V., any security holder of Wright Medical Group N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes 7,273 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document |
| August 06, 2019 Filed Aug 7, 2019 01:32 UTC | VAPOTHERM INC VAPO · Entity 87270 | PurchaseCommon Stock | 30,000 | $14.50 | $435,000.00 |
DisclosureSEC source: 0001562180-19-004197 · primarydocument.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,101 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.